13,913 Becton, Dickinson and Company $BDX Shares Bought by JGP Wealth Management LLC

Key Points

• JGP Wealth Management increased its Becton, Dickinson and Company stake by 700.6% in the third quarter, acquiring 13,913 additional shares and bringing its total holdings to 15,899 shares valued at approximately $2.85 million.
• Institutional investors own 86.97% of BDX, while insiders own 0.40%; company executives sold 6,906 shares worth roughly $1.27 million over the past three months under pre-arranged trading plans.
• BDX reported quarterly adjusted earnings of $3.23 per share and revenue of $4.98 billion, beating estimates, while analysts maintain an average “Hold” rating with a $185.07 target price. The company also pays a $1.05 quarterly dividend, yielding about 2.2%.

JGP Wealth Management LLC increased its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 700.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,899 shares of the medical instruments supplier's stock after acquiring an additional 13,913 shares during the period. JGP Wealth Management LLC's holdings in Becton, Dickinson and Company were worth $2,846,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Auto Owners Insurance Co boosted its holdings in Becton, Dickinson and Company by 22,225.2% during the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier's stock worth $790,079,000 after acquiring an additional 40,528,680 shares during the last quarter. BlackRock Inc. purchased a new stake in shares of Becton, Dickinson and Company in the second quarter valued at about $3,721,533,000. Bank of America Corp DE purchased a new stake in shares of Becton, Dickinson and Company in the second quarter valued at about $474,993,000. First Eagle Investment Management LLC lifted its position in shares of Becton, Dickinson and Company by 15.8% during the second quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier's stock valued at $2,090,675,000 after purchasing an additional 1,887,224 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new position in shares of Becton, Dickinson and Company during the second quarter valued at about $247,372,000. Institutional investors own 86.97% of the company's stock.

Insider Activity

In related news, EVP Michael Feld sold 165 shares of the company's stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the transaction, the executive vice president owned 19,720 shares in the company, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the company's stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the transaction, the chief executive officer owned 110,163 shares in the company, valued at approximately $20,380,155. The trade was a 3.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 6,906 shares of company stock valued at $1,265,855 in the last three months. Company insiders own 0.40% of the company's stock.

Becton, Dickinson and Company Trading Up 2.5%

Shares of Becton, Dickinson and Company stock opened at $188.35 on Tuesday. The firm has a market cap of $51.90 billion, a PE ratio of 56.73, a P/E/G ratio of 12.39 and a beta of 0.21. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $193.07. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. The stock has a fifty day moving average price of $182.70 and a 200-day moving average price of $162.80.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping analysts' consensus estimates of $3.14 by $0.09. The company had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm's quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the firm earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities research analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th were given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend was Wednesday, September 9th. Becton, Dickinson and Company's dividend payout ratio is currently 126.51%.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on BDX shares. Jefferies Financial Group restated a "buy" rating and set a $210.00 price target on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. Stifel Nicolaus set a $195.00 price objective on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Wells Fargo & Company lifted their target price on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an "equal weight" rating in a research report on Friday, August 7th. Piper Sandler boosted their target price on Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a "neutral" rating in a research note on Friday, August 7th. Finally, Bank of America upped their target price on Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a "neutral" rating in a report on Monday, August 31st. Seven analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $185.07.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD's Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.